Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (30211)	1/13/2000 1:31:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

<I don't think I ever commented on future (or past) sales> Ok Hank, so you expect me to believe that you have only commented on the speed of the FDA approval but not how it was the first step toward profitability. There were many posts on uses and sales and profit projections. The simple question everyone wants your opinion on is "Is Panretin a flop"? If no in what ways will it help Lgnd's march to profitability?

To: Henry Niman who wrote (30211)	1/13/2000 1:37:00 PM
From: Torben Noerup Nielsen	Respond to of 32384

Henry, Sadly, AIDS is a huge problem. But the biggest numbers of patients exists in underdeveloped countries and they do not have the resources to adequately medicate AIDS patients. What concerns me most about AIDS is that the people suffering from it tend to get all sorts of other opportunistic diseases and that has the potential to allow the HIV virus to pick up useful little snippets of genetic material from relatively benign but highly contagious entities. And when that happens, we've got a big problem. Thanks, Torben